Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02440958
Recruitment Status : Completed
First Posted : May 12, 2015
Last Update Posted : February 18, 2019
Information provided by (Responsible Party):
Yonsei University

Brief Summary:
Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Since the approval of gemcitabine as a standard treatment for advanced pancreatic patients, no drug or combination of drugs has significantly improved the prognosis. Recently, as compared with gemcitabine, FOLFIRINOX was associated with a survival advantage (11.1 vs 6.8 months), but had increased toxicity. In some retrospective studies, modified FOLFIRINOX regimen (60/120 mg/m2 of oxaliplatin and irinotecan) has an improved safety profile in digestive malignancies. The purpose of this phase II multicenter study was to investigate the efficacy and safety in patients with pancreatic cancer who progressed in gemcitabine-based first line chemotherapy.

Condition or disease Intervention/treatment Phase
Pancreatic Ductal Adenocarcinoma Drug: modified FOLFIRINOX regimen Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : August 28, 2015
Actual Primary Completion Date : March 2, 2017
Actual Study Completion Date : March 2, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: modified FOLFIRINOX Drug: modified FOLFIRINOX regimen
Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks

Primary Outcome Measures :
  1. True response rate [ Time Frame: within 16 weeks ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 6, 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage)
  • Refractory or progress to Gemcitabine based 1st line chemotherapy
  • Older than 19 years old and younger than 75 years old
  • Life expectancy> 3 months
  • ECOG Performance status ≤2
  • Only patients with measurable lesions in imaging study
  • Adequete BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl)
  • Adequete liver function (total bilirubin < 1.5 X the upper limits of normal (ULN), AST and ALT <3 X UNL, and alkaline phosphatases < 3 X ULN or < 5 x ULN in case of liver involvement)
  • Adequete renal function (serum creatinine < 1.5 mg/dl)
  • Adequete cardiopulmonary function

Exclusion Criteria:

  • Pathologically confirmed another type of pancreatic cancer (except ductal adenocarcinoma)
  • Metastatic adenocarcinoma of originating at other organs
  • Evidence with CNS metastasis
  • Active infection
  • Uncontrolled serious medical or psychiatric illness which can induce toxicity ro complication of treatment, such as inability to swallow, lacking physical integrity of the gastrointestinal tract, malabsorption syndrome, or active ulceration at upper gastrointestinal tract.
  • Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin
  • Participation in any other investigational drug study within 1 month
  • No signed informed consent

Layout table for additonal information
Responsible Party: Yonsei University Identifier: NCT02440958    
Other Study ID Numbers: 4-2014-0973
First Posted: May 12, 2015    Key Record Dates
Last Update Posted: February 18, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents